Nuvve Appoints Antonie Wobbe Ploegsma and Andrew J. Ritter as Independent Directors

Nuvve Holding Corp. appointed Antonie Wobbe Ploegsma and Andrew J. Ritter to its board as independent directors, the company announced on November 5, 2026. Business Wire reported that the two bring experience in corporate strategy, corporate finance, capital markets and investor relations as Nuvve rebuilds its financial foundation and works to regain a listing on a national securities exchange.

Nuvve's Two New Independent Directors

Ploegsma is Vice President and Head of Investor Relations & Capital Markets at Prairie Operating Co., where he leads engagement with shareholders, research analysts, investment banks and other capital-markets participants. He previously was Vice President of Investor Relations & Capital Markets at Lilis Energy, Inc. and Vice President, Energy Investment Banking at FBR & Co. He holds an MBA from Rice University's Jones Graduate School of Business.

Ritter serves in Corporate Strategy and Portfolio Management at Future Solution Investments, an investment firm focused on special-situation businesses. From 2023 to 2026 he was Chief Executive Officer of Cairns Health, a healthcare AI company backed by Vinod Khosla and Lightspeed Venture Partners. From 2021 to 2023 he was CEO of Docbot, Inc., a Khosla Ventures-backed gastrointestinal AI company acquired by Satisfai Health in 2023. He co-founded Ritter Pharmaceuticals, Inc. and served as its CEO until its May 2020 merger with Qualigen, Inc., where he advanced its lead drug candidate through a Phase 3 trial and helped lead its Nasdaq initial public offering. He holds an MBA from The Wharton School of the University of Pennsylvania.

"Wobbe and Andrew join our board at an important moment for Nuvve," said Gregory Poilasne, CEO of Nuvve. "We are rebuilding the company: strengthening our balance sheet, our governance and our relationships with investors, with the goal of returning to a national securities exchange."

Ploegsma said the work now is to strengthen the balance sheet and earn investor confidence through consistent delivery of objectives. Ritter said the decisions that matter most are where to focus capital and prioritize relationships.

Nuvve's Funding and Japan Listing Plans

According to akta.pro company records, Nuvve has 13 funding rounds on record, including a $14.7 million post-IPO equity round in August 2026, a $1.3 million round in May 2026, a $6 million round in December 2025 and a $4.8 million round in July 2025. The same records show total funding of $62.8 million and a headcount range of 11-50. In May 2026, Nuvve Japan K.K. raised 200 million yen through JKISS-style stock acquisition rights and established an IPO preparatory office targeting a potential public listing during fiscal year 2026.

Nuvve's Path From Nasdaq to the OTCQB

Nuvve received a determination from the NASDAQ Hearing Panel on July 22, 2026, resulting in the suspension of its common stock trading starting July 24, 2026, Seeking Alpha reported. The company began trading on the OTCQB market under the symbol NVVE as of August 10, according to Seeking Alpha. In October 2026, Nuvve launched Astrea, a standalone company offering AI-based market and load forecasting to electric cooperatives and municipal utilities, with Nuvve retaining a controlling interest, Stock Titan reported.